Home » Newsletters » BioWorld Science

BioWorld Science

May 29, 2019

View Archived Issues

Glial dysfunction is part of chemo brain

TLRs in DIO

"R-AI-diologist" can outperform radiologists in lung cancer screening

In infection, T cells are cachexia drivers

Food antigens drive IgE antibody elevation if no commensals present

SNG-001 for virus-induced exacerbations of lung disease

Enrollment opens in phase III study of HLX-10 in esophageal squamous cell carcinoma

Soligenix obtains support to study IDRs as bacterial threat countermeasures

Mutation in mevalonate kinase found in porokeratosis ptychotropica

Integral Molecular achieves milestone in Daiichi Sankyo immuno-oncology collaboration

Ziopharm and NCI sign T-cell technology licensing agreement

Bristol-Myers Squibb patents farnesoid X receptor agonists

ProMIS identifies antibody candidates that selectively bind toxic oligomers of tau for Alzheimer's

Researchers develop new murine model of dystrophic epidermolysis bullosa-squamous cell carcinoma

AbbVie and Calico Life Sciences jointly describe EIF2B activators

Idorsia prepares and tests antibacterial compounds

P2X3 and/or P2X2/3 receptor antagonists described in Beijing Tide Pharmaceutical patent

AiCuris reports agents for the treatment of HBV infections

In vivo antitumoral activity seen with mixture of cytokine-encoding mRNAs

FDA approves Revlimid with rituximab for previously treated FL and marginal zone lymphoma

Zynerba initiates phase II trial of Zygel to treat behavioral symptoms in 22q11.2 deletion syndrome

Eli Lilly divulges BTK inhibitors in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...